Choosing the Right Path
September 30, 2015 – Mike Hennessy, Sr.
Resolving a Controversy: The Value of PSA Screening
September 30, 2015 – Debu Tripathy
Medical Illustration: Prostate Cancer
September 30, 2015 – Pam Curry
Where Are the Men? BRCA Mutations and Male Awareness
September 28, 2015 – Linda Penwarden, MN, RN, AOCN
Surgery or Radiation for Prostate Cancer: What Determines the Choice?
September 25, 2015 – Maureen Salamon
Marathon Men: Living Longer With Prostate Cancer
September 24, 2015 – Roxanne Nelson, RN
Delicate Difference: More Surgical Options for Prostate Cancer
September 24, 2015 – Beverly A. Caley
Satisfaction Guaranteed: Sexual Activity After Prostate Cancer Therapy
September 23, 2015 – Erik Ness
On Guard: Gauging Aggressiveness of Prostate Cancer Aids Decision Making
September 21, 2015 – Jeanne Erdmann
Scanning the Horizon: Advances in Radiation Treatment for Prostate Cancer
September 30, 2015 – Maureen Salamon
Choosing the Right Path
September 30, 2015 – Mike Hennessy, Sr.
Resolving a Controversy: The Value of PSA Screening
September 30, 2015 – Debu Tripathy
Medical Illustration: Prostate Cancer
September 30, 2015 – Pam Curry
Where Are the Men? BRCA Mutations and Male Awareness
September 28, 2015 – Linda Penwarden, MN, RN, AOCN
Currently Viewing
Surgery or Radiation for Prostate Cancer: What Determines the Choice?
September 25, 2015 – Maureen Salamon
Delicate Difference: More Surgical Options for Prostate Cancer
September 24, 2015 – Beverly A. Caley
Satisfaction Guaranteed: Sexual Activity After Prostate Cancer Therapy
September 23, 2015 – Erik Ness
On Guard: Gauging Aggressiveness of Prostate Cancer Aids Decision Making
September 21, 2015 – Jeanne Erdmann
Scanning the Horizon: Advances in Radiation Treatment for Prostate Cancer
September 30, 2015 – Maureen Salamon

Surgery or Radiation for Prostate Cancer: What Determines the Choice?

Whether to opt for surgery or radiation to treat localized prostate cancer depends mainly on the stage and grade of disease.
BY Maureen Salamon
PUBLISHED September 25, 2015
For localized disease, guidelines state that both surgery and radiation are acceptable forms of treatment, and men in this category make up a large number of cases. According to data from the Surveillance, Epidemiology, and End Results (SEER) program, localized disease accounts for about 80 percent of the nearly 221,000 new cases projected for 2015 in the United States.

“It’s mostly early-stage cancers in which radiation therapy is competing with surgery,” says Dorin Todor, director of the brachytherapy program at Virginia Commonwealth University’s Massey Cancer Center in Richmond. “Surgery doesn’t make much sense for anything but early-stage prostate cancer, because if more than the prostate is involved, you’ll need some form of systemic approach.”

To help make a sound decision, patients should consider the following factors.

> AGE: Younger patients can better tolerate the general anesthesia that’s used in the vast majority of surgical cases, but new minimally invasive techniques (such as robot-assisted surgery) have made surgery a broader option, says James B. Yu, assistant professor of therapeutic radiology at Yale University School of Medicine in New Haven, Conn.

> COST: Insurance coverage varies, but external beam radiation therapy of any type might be more expensive than surgery, according to a 2013 study in the British Journal of Urology International. Researchers found that the costs ranged from about $20,000 for a robot-assisted prostatectomy for low-risk cancer to approximately $50,000 for combined radiation therapy for high-risk cancer. Brachytherapy, however, may be cheaper than surgery. Patients should always discuss the cost of treatment with their health care providers.

> SIDE EFFECTS: Any side effects from surgery — even the nerve-sparing type — tend to show up immediately, whereas radiation takes time to produce some of the same changes, experts say. (Which side effects occur and their frequencies vary from patient to patient, regardless of the choice.) For example, about half the men who had normal erections prior to EBRT became impotent within five years, and about one-third of the men who received brachytherapy experienced incontinence.

“We’ve made great strides over the past couple of decades, and prostate cancer remains a very curable disease for the most part,” Yu says. “That’s why we’re focusing so much on side effects and cost. In a way, focusing on these subtle questions is a good problem to have, since so many of these men go on to live such good, long lives.”
Be the first to discuss this article on CURE's forum. >>
Talk about this article with other patients, caregivers, and advocates in the Prostate Cancer CURE discussion group.

Related Articles

1
×

Sign In

Not a member? Sign up now!
×

Sign Up

Are you a member? Please Log In